Viral Hepatitis

To date, five viruses have been identified that target the liver and cause inflammatory infection. These viruses are referred to by the letters A, B, C, D and E, and vary according to their transmission mode (fecal-oral for A and E, parenteral for B and C) and their aggressive profile. Viral hepatitis is a major health problem with approximately half a billion people infected world-wide. The infection is characterized by mild to severe disease, including jaundice, fever, myalgia, nausea, fatigue, vomiting, fatty liver, cirrhosis, liver failure and liver cancer. Dott. Russo’ group is interested in clinical outcomes, translational studies, and therapeutic clinical trials for chronic hepatitis B and  C and liver transplant-related issues.


  1. Russo FP, Zanetto A, Campello E, Bulato C, Shalaby S, Spiezia L, Gavasso S, Franceschet E, Radu C, Senzolo M, Burra P, Lisman T, Simioni P. Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. Liver Int. 2018 May 8. doi: 10.1111/liv.13873
  2. Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego AL, Brunetto MR, Raimondo G, Taliani G, Iannone A, Russo FP, et al; PITER collaborating group. Forecasting Hepatitis C liver disease burden on real life data. Does the hidden iceberg matter to reach the elimination goals? Liver Int. 2018 Jun 14. doi: 10.1111/liv.13901.
  3. Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L, Cavalletto L, Gambato M, Russo FP, Burra P, Vincenzi V, Scotton PG, Panese S, Tempesta D, Bertin T, Carrara M, Carlotto A, Capra F, Carolo G, Scroccaro G, Alberti A. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. J Hepatol. 2018 Mar 16. pii: S0168-8278(18)30172-7
  4. Kondili LA, Romano F, Rolli FR, Ruggeri M, Rosato S, Brunetto MR, Zignego AL, Ciancio A, Di Leo A, Raimondo G, Ferrari C, Taliani G, Borgia G, Santantonio TA, Blanc P, Gaeta GB, Gasbarrini A, Chessa L, Erne EM, Villa E, Ieluzzi D, Russo FP, et al PITER Collaborating Group. Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. Hepatology. 2017 Dec;66(6):1814-1825.
  5. Schiavinato A, Zanetto A, Pantano G, Tosato F, Nabergoj M, Fogar P, Piva E, Gambato M, Franceschet E, Floreani A, Farinati F, Burra P, Russo FP*, Plebani M. Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents. J Viral Hepat. 2017 Dec;24(12):1168-1176.*Co-corresponding author


-  2015: Open Source on HBV

-  2016: "Evaluation of new circulating markers in patients with HCV-related liver disease undergoing IFN-free therapy”

-  National Basic Research Activities

-  2018: "Evaluation of new circulating markers in patients with HCV-related liver disease undergoing IFN-free therapy”

People involved:

Francesco Paolo Russo, Associate Professor
Fabio Farinati, Full Professor
Patrizia Burra, Full Professor
Annarosa Floreani, Associate Professor

Group members:

Martina Gambato (consultant Hepatologist), Alberto Zanetto, Alberto Ferrarese, Salvatore Sciarrone, Sara Shalaby  and Martina Tessari (GI and Liver Fellows), Enrica Franceschet (Research Nurse)